Studies
Resistance to Checkpoint Blockade Therapy Through Inactivation of Antigen Presentation
Resistance to Checkpoint Blockade Therapy Through Inactivation of Antigen Presentation
Request Access
Overview
Selected Publications (7)
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll. (2012). Nature Reviews Cancer. Cited 12,491 times.
https://doi.org/10.1038/nrc3239
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
J. Zaretsky, A. García-Díaz, D. Shin, et al.. (2016). The New England journal of medicine. Cited 2,644 times.
https://doi.org/10.1056/NEJMoa1604958
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
E. V. Van Allen, Diana Miao, B. Schilling, et al.. (2015). Science. Cited 2,521 times.
https://doi.org/10.1126/science.aad0095
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Jeffrey S. Weber, S. D’Angelo, D. Minor, et al.. (2015). The Lancet. Oncology. Cited 2,502 times.
https://doi.org/10.1016/S1470-2045(15)70076-8
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao, L. Shi, Hao Zhao, et al.. (2016). Cell. Cited 1,142 times.
https://doi.org/10.1016/j.cell.2016.08.069
Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes
M. Bernal, F. Ruiz-Cabello, A. Concha, et al.. (2012). Cancer Immunology, Immunotherapy. Cited 118 times.
https://doi.org/10.1007/s00262-012-1321-6
Beta2‐microglobulin mutations in microsatellite unstable colorectal tumors
M. Kloor, S. Michel, Boris Buckowitz, et al.. (2007). International Journal of Cancer. Cited 114 times.
https://doi.org/10.1002/ijc.22691
